NCT07352566

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Utilization of a Cutaneous Therapy In Situ Microdevice

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Conditions

• Psoriasis
• Atopic Dermatitis

Interventions

Type	Name	Description
DEVICE	In situ cutaneous microdevice	The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.
DRUG	Triamcinolone	Triamcinolone
DRUG	5-Fluorouracil	5-fluorouracil
DRUG	Calcipotriene	Calcipotriene
DRUG	Tapinarof	Tapinarof
DRUG	Crisaborole	Crisaborole
DRUG	Tacrolimus	Tacrolimus
DRUG	Adalimumab	Adalimumab
DRUG	Etanercept	Etanercept
DRUG	Certolizumab	Certolizumab
DRUG	Infliximab	Infliximab
DRUG	Secukinumab	Secukinumab
DRUG	Ixekizumab	Ixekizumab
DRUG	Apremilast	Apremilast
DRUG	Risankizumab	Risankizumab
DRUG	Ustekinumab	Ustekinumab
DRUG	Hydroxychloroquine	Hydroxychloroquine
DRUG	Methotrexate	Methotrexate
DRUG	Mycophenolate	Mycophenolate
DRUG	Azathioprine	Azathioprine
DRUG	Chloroquine	Chloroquine
DRUG	Cyclosporine	Cyclosporine
DRUG	Tofacitinib	Tofacitinib
DRUG	Deucravacitinib	Deucravacitinib
DRUG	Dupilumab	Dupilumab
DRUG	Tralokinumab	Tralokinumab
DRUG	Guselkumab	Guselkumab
DRUG	Tildrakizumab	Tildrakizumab
DRUG	Baractinib	Baractinib
DRUG	Abrocitinib	Abrocitinib
DRUG	Upadacitinib	Upadacitinib
DRUG	Lebrikizumab	Lebrikizumab
DRUG	Nemolizumab	Nemolizumab
DRUG	Ruxolitinib	Ruxolitinib
DRUG	Bimekizumab	Bimekizumab
DRUG	Roflumilast	Roflumilast

Timeline

• Start date: 2026-01-01
• Primary completion: 2030-06-01
• Completion: 2030-06-01
• First posted: 2026-01-20
• Last updated: 2026-01-20

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study